A rapid solid form risk assessment workflow for ophthalmic drug candidates.

Objective: This work introduces a material-sparing process that rapidly screens the solid form landscape for ophthalmic compound candidates.

Significance: Crystalline form of compound candidates generated by a Form Risk Assessment (FRA) can be used to reduce their downstream development risk.

Methods: This workflow evaluated nine model compounds with various molecular and polymorphic profiles by using less than 350 mg of drug substances.